24 April 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Notice of Results and Investor Presentation via Investor Meet Company

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, will announce its Preliminary Results for the year ended 31 December 2024 on Thursday 1^st May 2025.

Rob Baker, Joint Managing Director and Chief Operating Officer, and Ronald Openshaw, (acting Chief Financial Officer), will provide a live presentation via Investor Meet Company at 11:00 BST on Thursday 1^st May 2025.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 30 April 2025, 9:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Cognitions Holdings plc via:

https://www.investormeetcompany.com/cambridge-cognition-holdings-plc/register-investor

Investors who already follow Cambridge Cognitions Holdings plc on the Investor Meet Company platform will automatically be invited.

- Ends -

Enquiries:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital health products to advance brain health research and treatment.

The Company offers four core products:

· CANTAB® assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks;

· a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture;

· rater training services that standardise assessment delivery and scoring across clinical trials; and,

· quality assurance tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money.

These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information, visit: www.cambridgecognition.com